Reflective of the proteomics analyses, both human T24 and murine G69 bladder cancer cells displayed enrichment of cell surface CRT and HSP70 after 48 h of gemcitabine treatment in vitro, when compared to vehicle-treated control cells (Fig. 2a). Here, CALR is linked to urinary bladder carcinoma.